July 26, 2017 7:43 AM ET

Life Sciences Tools and Services

Company Overview of Imanis Life Sciences, LLC

Company Overview

Imanis Life Sciences, LLC, a non-invasive imaging solutions company, provides reporter gene imaging vectors, cells, services, and support. It offers ready to use lentivectors for gene transfer to primary cells and cell lines for use in vitro characterization studies and in vivo studies in research animals. The company also provides contract imaging services, including study design, imaging contract, and in vitro and in vivo studies; and data processing services through non-invasive imaging solutions that include quantitative analyses of SPECT/CT or PET/CT data in various file formats. Imanis Life Sciences, LLC was incorporated in 2012 and is based in Rochester, Minnesota.

221 1st Avenue SW

Suite 102

Rochester, MN 55902

United States

Founded in 2012



Key Executives for Imanis Life Sciences, LLC

Founding Member, Chief Executive Officer, President and Member of The Strategic Advisory Board
Founding Member, Chief Operating Officer, Secretary and Member of The Strategic Advisory Board
Co-Founder and Chairman of the Strategic Advisory Board
Founding Member and Member of the Strategic Advisory Board
Compensation as of Fiscal Year 2017.

Imanis Life Sciences, LLC Key Developments

Imanis Life Sciences Launches Line of Oncolytic Vaccinia Viruses Encoding Reporter Genes from Genelux Corporation

Imanis Life Sciences announced the launch of a new product line of oncolytic vaccinia viruses for virotherapy research. These viruses are licensed from Genelux Corporation as part of Genelux's proprietary, vaccinia virus-based technology platform for research use. Oncolytic virotherapy has emerged as a new immunotherapeutic treatment modality that uses replication-competent viruses to target and destroy cancer cells. In 2015, the U.S. Food and Drug Administration approved the first oncolytic virus, T-VEC, for the treatment of metastatic melanoma. Researchers rely on well-characterized oncolytic viruses to establish equivalence or superiority in preclinical studies. Imanis repository of well-characterized recombinant oncolytic viruses includes measles virus, vesicular stomatitis virus, herpes simplex virus, and vaccinia virus to facilitate this research. Imanis will initially offer two vaccinia viruses engineered to express reporter genes to facilitate tracking in culture dishes and in animals, and will launch several other vaccinia viruses by the end of 2017. One of the vaccinia viruses currently available from Imanis encodes the sodium iodide symporter (NIS). NIS imaging by SPECT or PET provides a high-resolution 3D picture of where the virus is in the animal. The two viruses are: VV(Li)-RucGFP-hNIS-tRFP, which encodes optical imaging reporter genes and the NIS protein; and VV(Li)-RucGFP-mTyr-GusA, which encodes tyrosinase, the primary enzyme responsible for melanin production, allowing it to be imaged by photoacoustic imaging.

Vyriad Signs License Collaboration Agreement with Imanis Life Sciences to Develop in Vitro and in Vivo Theranostic Tests

Vyriad announced the signing of a license collaboration agreement with Imanis Life Sciences to develop in vitro and in vivo theranostic tests that assess the probability that a cancer patient will be responsive to Vyriad's oncolytic virus therapeutics. The tests use recombinant vesicular stomatitis viruses that have been engineered to incorporate theranostically informative reporter genes and permit their safe handling as diagnostic reagents in the hospital laboratory setting. The test kits are being developed and preclinically validated at Imanis Life Sciences, while clinical validation is anticipated in Vyriad-sponsored clinical trials through 2017 and beyond. Under the terms of the agreement, Imanis Life Sciences will use its proprietary virus technology to develop and preclinically validate companion diagnostic tests that can be used to predict the likelihood of a clinical response to oncolytic virotherapy. Vyriad will select one or two test formats for further evaluation in Vyriad-sponsored clinical trials to determine their predictive power. Vyriad plans to pursue clinical validation and regulatory approval for the tests in the human and veterinary settings. Once approved, Imanis will grant Vyriad a nonexclusive license to use the companion diagnostic tests to accelerate development of its proprietary oncolytic viruses derived from the company's vesicular stomatitis virus (VSV), measles virus, or other Vyriad platforms.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Imanis Life Sciences, LLC, please visit www.imanislife.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.